Genomic profiling of breast cancer in Sweden
SCAN-B: The Sweden Cancerome Analysis Network - Breast Initiative
This study looks at the genetic makeup of breast cancer in over 20,000 patients in Sweden to see how it can help tailor treatments and improve outcomes for those affected.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 20000 (estimated) |
| Sex | All |
| Sponsor | Lund University Academic / other |
| Locations | 9 sites (Halmstad and 8 other locations) |
| Trial ID | NCT02306096 on ClinicalTrials.gov |
What this trial studies
This observational study evaluates the genomic profiles of breast cancer through whole transcriptome RNA-sequencing in a prospective, population-based manner. It aims to analyze gene expression, mutational profiles, and transcript isoform-level data in relation to patient information and clinical outcomes. The goal is to develop new molecular diagnostic assays that can personalize treatment and improve patient outcomes. The study has enrolled over 20,000 patients, representing a significant portion of breast cancer cases in Sweden.
Who should consider this trial
Good fit: Ideal candidates include individuals with a suspicion or confirmed diagnosis of primary breast cancer who can provide informed consent.
Not a fit: Patients without a confirmed diagnosis of breast cancer or those who do not provide informed consent may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more personalized and effective treatment options for breast cancer patients.
How similar studies have performed: Other studies utilizing genomic profiling in cancer have shown promise, indicating that this approach may yield valuable insights and advancements in breast cancer treatment.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * suspicion or confirmed diagnosis of primary breast cancer * signed informed consent Exclusion Criteria: * lack of signed informed consent
Where this trial is running
Halmstad and 8 other locations
- Hallands Hospital Halmstad — Halmstad, Sweden (Suspended)
- Helsingborg Hospital — Helsingborg, Sweden (Recruiting)
- Kirurgiska kliniken — Jönköping, Sweden (Recruiting)
- Blekinge County Hospital — Karlskrona, Sweden (Recruiting)
- Central Hospital Kristianstad — Kristianstad, Sweden (Recruiting)
- Skåne University Hospital — Lund, Sweden (Recruiting)
- Skåne University Hospital — Malmö, Sweden (Recruiting)
- Uppsala University Hospital — Uppsala, Sweden (Recruiting)
- Central Hospital Växjö — Vaxjo, Sweden (Recruiting)
Study contacts
- Principal investigator: Christer Larsson, PhD — Lund University
- Study coordinator: Åke Borg, PhD
- Email: ake.borg@med.lu.se
- Phone: +46-46-2752552
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.